F11R antibody (Extracellular Domain) (FITC)

Catalog No. ABIN1106269

This Mouse Monoclonal antibody specifically detects F11R in WB, FACS, IF and IHC (fro). It exhibits reactivity toward Human.

Quick Overview for F11R antibody (Extracellular Domain) (FITC) (ABIN1106269)

Target: F11R (F11 Receptor (F11R))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This F11R antibody is conjugated to FITC

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: BV16

Product Details anti-F11R Antibody (FITC)

Binding Specificity: Extracellular Domain

Specificity: The monoclonal antibody BV16 recognizes the human junction adhesion molecule (JAM)-A.

Cross-Reactivity (Details): Species reactivity (tested):Human

Purification: Potein G

Immunogen: Fusion protein consisting of the extracellular domain of human JAM and the Fc portion of human IgGs

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 1 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Prior to reconstitution store at 2-8 °C. Following reconstitution store undiluted at 2-8 °C for one month or or (in aliquots) at -20 °C for longer.

Target Details for F11R

Target: F11R (F11 Receptor (F11R))

Alternative Name: CD321 / JAM1

Background: Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization and their molecular weight is about 30-40 kDa. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the beta2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role for JAM-A in the initiation of atherosclerosis since JAM-A is upregulated on early atherosclerotic endothelium. The adhesion of activated platelets on the activated endothelium is mediated by homophilic interactions of JAM-A.Synonyms: F11R, JAM-A, JCAM, Junctional adhesion molecule 1, Junctional adhesion molecule A, PAM1, Platelet F11 receptor, Platelet adhesion molecule 1

Gene ID: 50848

NCBI Accession: NP_058642

UniProt: Q9Y624

Pathways: Cell-Cell Junction Organization